Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

November 10, 2021

Study Completion Date

November 19, 2021

Conditions
Hypertension
Interventions
DRUG

Amlodipine

Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.

Trial Locations (2)

EC1m 6BQ

William Harvey Research Institute Clinical Research Centre, Queen Mary University of London, London

EC1M 6BQ

Queen Mary University London, London

Sponsors
All Listed Sponsors
collaborator

Closed Loop Medicine Ltd

UNKNOWN

collaborator

Innovate UK

OTHER_GOV

lead

Queen Mary University of London

OTHER

NCT04559074 - Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension | Biotech Hunter | Biotech Hunter